HealthyPhase 1MDRNCT04849013
Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness
A Phase 1 study testing Mescaline 100mg, Mescaline 200mg and Mescaline 400mg in people with Healthy, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
Mescaline (the active substance in Peyote and San Pedro cacti) is a classic and long known serotonergic psychedelic substance (hallucinogen) that is widely used for recreational, spiritual, and/or ethno medical purposes. Despite its long history, modern data on the acute effects of mescaline on human is lacking. Read more about this study
- Who is it for?
- Ages 25 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Mescaline 100mg, Mescaline 200mg and Mescaline 400mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 16 participants
- Where
- 1 siteSwitzerland
- Study dates
- 11 Aug 2021to 27 Mar 2023
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age between 25 and 65 years old
- Sufficient understanding of the German language
- Understanding of procedures and risks associated with the study
- Willing to adhere to the protocol and signing of the consent form
- Willing to refrain from the consumption of illicit psychoactive substances during the study
- Abstaining from xanthine-based liquids from the evenings prior to the study sessions to the end of the study days
Show all 9Show fewer
- Willing not to drive a traffic vehicle or operate heavy machinery within 48 hours after substance administration
- Willing to use double-barrier birth control throughout study participation
- Body mass index between 18-29 kg/m2
Who cannot join
- Chronic or acute medical condition
- Current or previous major psychiatric disorder
- Psychotic disorder or bipolar disorder in first-degree relatives
- Hypertension (>140/90 mmHg) or hypotension (SBP10 cigarettes/day)
- Hallucinogenic substance use (not including cannabis) more than 20 times or any time within the previous two months
- Pregnancy or current breastfeeding
Show all 10Show fewer
- Participation in another clinical trial (currently or within the last 30 days)
- Use of medication that may interfere with the effects of the study medication
- Tobacco smoking (>10 cigarettes/day)
- Consumption of alcoholic beverages (>20 drinks/week)
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital Basel, Clinical Trial Unit
Basel, Canton of Basel-City, 4056
About this study
Mescaline (the active substance in Peyote and San Pedro cacti) is a classic and long known serotonergic psychedelic substance (hallucinogen) that is widely used for recreational, spiritual, and/or ethno medical purposes. Despite its long history, modern data on the acute effects of mescaline on human is lacking. Mescaline produces prototypical psychedelic effects, similar as lysergic acid diethylamide (LSD) and psilocybin. The serotonin 2A (5-HT2A) receptor is thought to primarily mediate acute alterations of consciousness induced by LSD and psilocybin. However, the contributory role of the 5-HT2A receptor in mescaline-induced alterations of consciousness is unclear. Using 5-HT2A receptor antagonist ketanserin, the psychedelic experience induced by LSD and psilocybin can be attenuated and shortened. The present study therefore explores the role the 5-HT2A receptor in mescaline-induced altered states of consciousness using escalating doses of mescaline and the 5-HT2A receptor blocker ketanserin administered before a high dose of mescaline.
Objective: The present MDR-study will characterize the subjective effects of different doses of mescaline using modern psychometric instruments and examine the contribution of the 5-HT2A receptor in the mescaline-induced alterations of consciousness.
Read more
Design: Double-blind, placebo-controlled, 6-period cross-over design with six treatment conditions. 1) Placebo (Pla + Pla), 2) 100 mg mescaline (Pla + 100mg mescaline), 3) 200 mg mescaline (Pla + 200mg mescaline), 4) 400 mg mescaline (Pla + 400mg mescaline), 5) 800 mg mescaline (Pla + 800mg mescaline), and 6) 40mg ketanserin and 800mg mescaline (Ket + 800mg mescaline).
Participants: 16 healthy participants aged ≥ 25 and ≤ 65 years (8 female, 8 male)
- Conditions
- Healthy
- Being tested
- Placebo, Mescaline 100mg, Mescaline 200mg, Mescaline 400mg, Mescaline 800mg
- Keywords
- Mescaline, Serotonin, Hallucinogen
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
Drug: Placebo Capsules containing mannitol looking identical to the other drugs Other: Placebo Capsules containing mannitol looking identical to the other drugs
Mescaline 100mgDrug
Drug: 100mg Mescaline per os, single dose
Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Mescaline 200mgDrug
Drug: 200mg Mescaline per os, single dose
Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Mescaline 400mgDrug
Drug: 400mg Mescaline per os, single dose
Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Mescaline 800mgDrug
Drug: 800mg Mescaline per os, single dose
Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Mescaline 800mg + Ketanserin 40mgDrug
Drug: 800mg Mescaline per os, single dose
Other: 40mg Ketanserin per os, single dose
| Study group | Role | What they receive |
|---|---|---|
| Placebo + Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
| Mescaline-100 + Placebo | Active comparator | Not described Receives: Drug: Mescaline 100mg |
| Mescaline-200 + Placebo | Active comparator | Not described Receives: Drug: Mescaline 200mg |
| Mescaline-400 + Placebo | Active comparator | Not described Receives: Drug: Mescaline 400mg |
| Mescaline-800 + Placebo | Active comparator | Not described Receives: Drug: Mescaline 800mg |
| Mescaline-800 + Ketanserin | Active comparator | Not described Receives: Drug: Mescaline 800mg + Ketanserin 40mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Altered States of Consciousness
5 Dimensions of Altered States of Consciousness (5D-ASC) assesses mood, anxiety, derealization, depersonalization, changes in perception, auditory alterations, and reduced vigilance. The questionnaire is consisting of 94 items to be rated on a visual analog scale (horizontal line, 100 mm, marked with "not at all" on the left and "extremely" on the right), with higher values indicating stronger effects. Subjects will mark the scale with vertical lines.
Measured: 18 months
Secondary outcomes (28)
Extent of subjective response over time
Visual Analog Scales (VAS) will be repeatedly used to assess subjective alterations in consciousness over time. VAS will be presented as 100 mm long horizontal lines marked with "not at all" on the left and "extremely" on the right. The following VAS will be used: "any drug effect", "good drug effect", "bad drug effect", "stimulated", "happy", "anxiety", "nausea", "alteration of vision", "alterations of hearing", "sounds seem to influence what I see", "alteration of sense of time", "the boundaries between myself and my surroundings seem to blur", "I am having insights into connections that previously puzzled me", "open", "talkative", and "trust". Subjects will mark the scale with vertical lines.
Measured: 18 months
Subjective mood ratings
Adjective Mood Rating Scale (AMRS) assesses the occurrence and intensity of 60 moods on a 4-point Likert scale ranging from "not at all" to "extremely".
Measured: 18 months
Subjective experiences of spiritual phenomenons
Spiritual Realms Questionnaire (SRQ) assesses the spiritual phenomenons elicited by psychedelic substances through 11 main questions to be answered on a total of 65 sub-ordered visual analog scales (horizontal line, 100 mm, marked with "no, at all" on the left and "yes, very strong" on the right).
Measured: 18 months
States of Consciousness
States of Consciousness Questionnaire (SCQ) assesses the emergence and intensity of phenomenons occurring in altered states of consciousness on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely").
Measured: 18 months
Mystical-type experiences
Mystical-type experience questionnaire (MEQ) assesses with 30 items (embedded into the SCQ) the mystical experiences on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely").
Measured: 18 months
Blood pressure
Blood pressure, assessed 20 times during each study session via systolic and diastolic blood pressure.
Measured: 18 months
Heart rate
Heart rate, assessed 20 times during each study session via heart rate, Emax.
Measured: 18 months
Body temperature
Body temperature assessed 20 times during each study session via tympanic body temperature.
Measured: 18 months
Pupil size
Pupil size, assessed 8 times during each study session via pupilometer.
Measured: 18 months
Mescaline concentrations in the blood
Mescaline and metabolites concentrations measured in the blood plasma, assessed 20 times during each study session via blood samples.
Measured: 18 months
Mescaline concentrations in the urine
Mescaline and metabolites concentration measured in the urine, assessed in the total amount collected during each study session.
Measured: 18 months
Effects on brain-derived neurotrophic factor (BDNF)
Plasma levels of brain-derived neurotrophic factor (BDNF), assessed 5 times during each study session via blood samples.
Measured: 18 months
Effects on inflammatory cytokines
Plasma levels of INF-gamma, TNFalpha, Interleukins, assessed 5 times during each study session via blood samples.
Measured: 18 months
Effects on oxytocin
Plasma levels of oxytocin, assessed 4 times during each study session via blood samples.
Measured: 18 months
Emotional effects
Multifaceted Empathy Test (MET), effects on empathy in computer tests, assessed one time during each study session.
Measured: 18 months
Effect moderation through personality traits I
Assessed one time during the screening via the NEO-Five-Factor-Inventory (NEO-FFI). The NEO-FFI assesses 5 personality traits (openness to experience, conscientiousness, extraversion, agreeableness and neuroticism) consisting of of 60 items. Each item is evaluated on a scale from -- "strong disagreement" to ++ "strong agreement".
Measured: 18 months
Effect moderation through personality traits II
Assessed one time during the screening via Freiburger Personality Inventory (FPI). The FPI-R version comprises 138 items and covers 12 dimensions of personality: life satisfaction, social orientation, performance orientation, inhibition, excitability, aggressiveness, stress, physical complaints, health concerns, openness, as well as the secondary factors according to Eysenck's Extraversion and Emotionality (Neuroticism). It uses a 2-point scale ("true" and "not true").
Measured: 18 months
Effect moderation through personality traits III
Assessed one time during the screening via Saarbrücker Personality Questionnaire (SPF). The SPF defines empathy as the "reactions of one individual to the observed experiences of another." It assesses 28-items on a 5-point Likert scale ranging from "Does not describe me well" to "Describes me very well". The measure has 4 subscales (Perspective Taking, Fantasy, Empathic Concern, Personal Distress) each made up of 7 different items.
Measured: 18 months
Effect moderation through personality traits IV
Assessed one time during the screening via HEXACO personality inventory (Honesty-Humility, Emotionality, Extraversion, Agreeableness, Conscientiousness, and Openness). The HEXACO consists of 100 items. Each item is evaluated on a scale from 1 "strong disagreement" to 5 "strong agreement".
Measured: 18 months
Effect moderation through personality traits V
Assessed one time during the screening via Defense Style Questionnaire (DSQ-40). The DSQ-40 can provide scores for 20 individual defenses, and scores for the three factors "mature", "neurotic", and "immature". Each item is evaluated on a scale from 1 to 9, where "1" indicates "completely disagree" and "9" indicates "fully agree".
Measured: 18 months
Psychological insight
Psychological insight questionnaire (PIQ), assesses painful insights during a psychedelic experience with 14 items (6-point Likert scale ranging from 0 ("not at all") to 5 ("extreme/more than ever before")).
Measured: 18 months
Effects on life satisfaction, well-being and appreciation I
Scale of Positive and Negative Experience (SPANE), assesses life satisfaction regarding the preceding week with12 items (5-point Likert scale ranging from 1 ("very rarely") to 5 ("very often")).
Measured: 18 months
Effects on life satisfaction, well-being and appreciation II
Berner Subjective Well-Being Questionnaire for Adolescents (BFW/E), assesses optimism with 8 items (6-point Likert scale ranging from 1 ("completely wrong") to 6 ("completely right")).
Measured: 18 months
Effects on life satisfaction, well-being and appreciation III
Global Life Satisfaction (GLS), assesses life satisfaction with a single question (ranging from 0 ("not at all satisfied") to 10 ("entirely satisfied")).
Measured: 18 months
Effects on life satisfaction, well-being and appreciation IV
Appreciation Scale (AS), assesses appreciation with 57 questions (7-point Likert scale ranging from 1 ("never") to 7 ("several times a day")).
Measured: 18 months
Incidence of Adverse Events before and during each study session
Major adverse events concerning the subject's health during study inclusion (if present) are registered by semi-structured interviews.
Measured: 18 months
Incidence of Adverse Events during each study session
List of complaints (LC), which covers the emergence of 66 complaints in a yes/no format, assessed three times during each study session.
Measured: 18 months
Electrical activity of the heart
Electrocardiogram (ECG) will be recorded twice during the study sessions (baseline and at peak drug effect) as well as on the screening exam to assess potential drug effects on the QTc interval.
Measured: 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Apr 2021
- Study start11 Aug 2021
- Primary completion27 Mar 2023
- Study completion27 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Matthias E Liechti, Prof. Dr. MD, Principal investigator, University Hospital, Basel, Switzerland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04849013
- Sponsor's protocol ID
- BASEC 2021-00035
- Acronym
- MDR
- Status last verified
- Mar 2023
- First submitted
- 26 Mar 2021
- Last updated
- 29 Mar 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Mueller L, Klaiber A, Ley L, Becker AM, Thomann J, Luethi D, Schmid Y, Liechti ME. Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants. Clin Pharmacokinet. 2025 Oct;64(10):1495-1506. doi: 10.1007/s40262-025-01544-x. Epub 2025 Jul 14.
PubMed 40658345
Study at a glance
From the registry record, last updated by the sponsor on 29 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness
- ClinicalTrials.gov ID
- NCT04849013
- Acronym / sponsor ID
- MDR / BASEC 2021-00035
- Conditions
- Healthy
- Keywords
- Mescaline, Serotonin, Hallucinogen
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- 11 Aug 2021 (actual)
- Primary completion
- 27 Mar 2023 (actual)
- Study completion
- 27 Mar 2023 (actual)
- First posted
- 19 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Mescaline (the active substance in Peyote and San Pedro cacti) is a classic and long known serotonergic psychedelic substance (hallucinogen) that is widely used for recreational, spiritual, and/or ethno medical purposes. Despite its long history, modern data on the acute effects of mescaline on human is lacking. Mescaline produces prototypical psychedelic effects, similar as lysergic acid diethylamide (LSD) and psilocybin. The serotonin 2A (5-HT2A) receptor is thought to primarily mediate acute alterations of consciousness induced by LSD and psilocybin. However, the contributory role of the 5-HT2A receptor in mescaline-induced alterations of consciousness is unclear. Using 5-HT2A receptor antagonist ketanserin, the psychedelic experience induced by LSD and psilocybin can be attenuated and shortened. The present study therefore explores the role the 5-HT2A receptor in mescaline-induced altered states of consciousness using escalating doses of mescaline and the 5-HT2A receptor blocker ketanserin administered before a high dose of mescaline.
Objective: The present MDR-study will characterize the subjective effects of different doses of mescaline using modern psychometric instruments and examine the contribution of the 5-HT2A receptor in the mescaline-induced alterations of consciousness.
Design: Double-blind, placebo-controlled, 6-period cross-over design with six treatment conditions. 1) Placebo (Pla + Pla), 2) 100 mg mescaline (Pla + 100mg mescaline), 3) 200 mg mescaline (Pla + 200mg mescaline), 4) 400 mg mescaline (Pla + 400mg mescaline), 5) 800 mg mescaline (Pla + 800mg mescaline), and 6) 40mg ketanserin and 800mg mescaline (Ket + 800mg mescaline).
Participants: 16 healthy participants aged ≥ 25 and ≤ 65 years (8 female, 8 male)
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Placebo + Placebo | Placebo comparator | Drug: Placebo |
| Mescaline-100 + Placebo | Active comparator | Drug: Mescaline 100mg |
| Mescaline-200 + Placebo | Active comparator | Drug: Mescaline 200mg |
| Mescaline-400 + Placebo | Active comparator | Drug: Mescaline 400mg |
| Mescaline-800 + Placebo | Active comparator | Drug: Mescaline 800mg |
| Mescaline-800 + Ketanserin | Active comparator | Drug: Mescaline 800mg + Ketanserin 40mg |
Who may qualify
- Ages
- 25 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Age between 25 and 65 years old
- Sufficient understanding of the German language
- Understanding of procedures and risks associated with the study
- Willing to adhere to the protocol and signing of the consent form
- Willing to refrain from the consumption of illicit psychoactive substances during the study
Key exclusion criteria (10 listed)
- Chronic or acute medical condition
- Current or previous major psychiatric disorder
- Psychotic disorder or bipolar disorder in first-degree relatives
- Hypertension (>140/90 mmHg) or hypotension (SBP10 cigarettes/day)
- Hallucinogenic substance use (not including cannabis) more than 20 times or any time within the previous two months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboDrug: Placebo Capsules containing mannitol looking identical to the other drugs Other: Placebo Capsules containing mannitol looking identical to the other drugs | Drug | Placebo + Placebo |
| Mescaline 100mgDrug: 100mg Mescaline per os, single dose Other: Placebo (Capsules containing mannitol looking identical to the other drugs) | Drug | Mescaline-100 + Placebo |
| Mescaline 200mgDrug: 200mg Mescaline per os, single dose Other: Placebo (Capsules containing mannitol looking identical to the other drugs) | Drug | Mescaline-200 + Placebo |
| Mescaline 400mgDrug: 400mg Mescaline per os, single dose Other: Placebo (Capsules containing mannitol looking identical to the other drugs) | Drug | Mescaline-400 + Placebo |
| Mescaline 800mgDrug: 800mg Mescaline per os, single dose Other: Placebo (Capsules containing mannitol looking identical to the other drugs) | Drug | Mescaline-800 + Placebo |
| Mescaline 800mg + Ketanserin 40mgDrug: 800mg Mescaline per os, single dose Other: 40mg Ketanserin per os, single dose | Drug | Mescaline-800 + Ketanserin |
Primary outcome
Altered States of Consciousness
Time frame: 18 months
5 Dimensions of Altered States of Consciousness (5D-ASC) assesses mood, anxiety, derealization, depersonalization, changes in perception, auditory alterations, and reduced vigilance. The questionnaire is consisting of 94 items to be rated on a visual analog scale (horizontal line, 100 mm, marked with "not at all" on the left and "extremely" on the right), with higher values indicating stronger effects. Subjects will mark the scale with vertical lines.
28 secondary outcomes
Extent of subjective response over time
Time frame: 18 months
Subjective mood ratings
Time frame: 18 months
Subjective experiences of spiritual phenomenons
Time frame: 18 months
States of Consciousness
Time frame: 18 months
Mystical-type experiences
Time frame: 18 months
Blood pressure
Time frame: 18 months
Heart rate
Time frame: 18 months
Body temperature
Time frame: 18 months
Pupil size
Time frame: 18 months
Mescaline concentrations in the blood
Time frame: 18 months
Mescaline concentrations in the urine
Time frame: 18 months
Effects on brain-derived neurotrophic factor (BDNF)
Time frame: 18 months
Effects on inflammatory cytokines
Time frame: 18 months
Effects on oxytocin
Time frame: 18 months
Emotional effects
Time frame: 18 months
Effect moderation through personality traits I
Time frame: 18 months
Effect moderation through personality traits II
Time frame: 18 months
Effect moderation through personality traits III
Time frame: 18 months
Effect moderation through personality traits IV
Time frame: 18 months
Effect moderation through personality traits V
Time frame: 18 months
Psychological insight
Time frame: 18 months
Effects on life satisfaction, well-being and appreciation I
Time frame: 18 months
Effects on life satisfaction, well-being and appreciation II
Time frame: 18 months
Effects on life satisfaction, well-being and appreciation III
Time frame: 18 months
Effects on life satisfaction, well-being and appreciation IV
Time frame: 18 months
Incidence of Adverse Events before and during each study session
Time frame: 18 months
Incidence of Adverse Events during each study session
Time frame: 18 months
Electrical activity of the heart
Time frame: 18 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Mar 2023.
- Derived from this study: PubMed 40658345Mueller L, Klaiber A, Ley L, Becker AM, Thomann J, Luethi D, Schmid Y, Liechti ME. Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants. Clin Pharmacokinet. 2025 Oct;64(10):1495-1506. doi: 10.1007/s40262-025-01544-x. Epub 2025 Jul 14.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Matthias E Liechti, Prof. Dr. MD principal investigator
University Hospital, Basel, Switzerland
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Mescaline 100mg, Mescaline 200mg and Mescaline 400mg in people with Healthy, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Altered States of Consciousness (time frame: 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04849013, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2023.